CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02507375
NCT02507375Phase 1Completed
CompareCT.gov

Phase Ib, Open-label, Multi-center Study of the Combination of Pertuzumab and Erlotinib in Patients With Locally Advanced or Metastatic (Stage IIIb/IV) NSCLC After Failure of at Least One Prior Chemotherapy Regimen.

Hoffmann-La Roche·interventional·Posted Jul 23, 2015·Updated Oct 16, 2015

In Brief

A Phase 1 clinical trial evaluating Erlotinib and Pertuzumab for Non-Small Cell Lung Cancer. Completed, enrolled 17 participants across 3 sites in 3 countries.

Detailed Summary

This study will assess the safety and tolerability, and make a preliminary assessment of activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed on at least one prior chemotherapy regimen. The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is less than 100 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesBelgium, Spain, United Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 23, 2015
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.9 years ago

Interventions

Erlotinibdrug

Erlotinib will be administered as oral tablets.

Pertuzumabdrug

Pertuzumab will be administered as intravenous (IV) infusion.